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Abstract: Acute pancreatitis (AP) is an inflammatory disease with varied severity, ranging from mild
local inflammation to severe systemic involvement resulting in substantial mortality. Early pathologic
events in AP, both local and systemic, are associated with vascular derangements, including
endothelial activation and injury, dysregulation of vasomotor tone, increased vascular permeability,
increased leukocyte migration to tissues, and activation of coagulation. The purpose of the review
was to summarize current evidence regarding the interplay between inflammation, coagulation
and endothelial dysfunction in the early phase of AP. Practical aspects were emphasized: (1) we
summarized available data on diagnostic usefulness of the markers of endothelial dysfunction
and activated coagulation in early prediction of severe AP; (2) we reviewed in detail the results of
experimental studies and clinical trials targeting coagulation-inflammation interactions in severe
AP. Among laboratory tests, D-dimer and angiopoietin-2 measurements seem the most useful in
early prediction of severe AP. Although most clinical trials evaluating anticoagulants in treatment
of severe AP did not show benefits, they also did not show significantly increased bleeding risk.
Promising results of human trials were published for low molecular weight heparin treatment. Several
anticoagulants that proved beneficial in animal experiments are thus worth testing in patients.
Keywords: acute pancreatitis; coagulation; endothelial injury; inflammation; laboratory markers
1. Introduction
Acute pancreatitis (AP) is the most common cause of acute hospital admissions among
gastrointestinal diseases, with the incidence of about 10–100 per 100,000 population [1–3]. Increasing
incidence has been recently reported in the USA and many European countries [1,4]. The disease is
characterized by the spectrum of severity: most cases are mild and self-limiting; however, about 30%
of cases are classified as moderately severe, and about 10% as severe according to the 2012 revision
of the Atlanta classification [5,6]. Organ failure is the main determinant of severity and the main
cause of early mortality, while secondary infections, including infected pancreatic necrosis and sepsis,
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are responsible for the late deaths [5]. Overall mortality in AP is about 3%–6%, whereas in severe
AP (SAP), it reaches 30% [1,6]. The high mortality is associated with the lack of specific treatment;
however, a decrease in mortality has been achieved thanks to improved intensive care and less invasive
surgical management in severe cases [1,6,7]. As indicated in current clinical guidelines [7], early
(within first 24 h from admission) and adequate fluid resuscitation decreases the rates of persistent
systemic inflammatory response syndrome (SIRS), organ failure and mortality.
Although the etiology of AP is complex [8], the two most common causes are biliary tract diseases
and excessive alcohol consumption [6]. Premature activation of digestive enzymes (most importantly,
trypsinogen into trypsin) within acinar cells is the key event in early pathogenesis of AP, leading to
destruction (autodigestion) of the pancreas [9,10]. Unconjugated bile acids and fatty acid ethyl esters
(the products of non-oxidative alcohol metabolism) cause mitochondrial injury and sustained increase in
intracellular Ca2+ concentrations in acinar cells, leading to inhibition of zymogen secretion and premature
activation of digestive enzymes [11,12]. Recent studies have shown that acinar cells form a functional
unit with ductal cells. Low doses of bile acids or alcohol cause increased secretion of bicarbonate-rich
fluid by pancreatic ductal cells that may protect acinar cells from the contact with toxic substances. To the
contrary, high concentrations of unconjugated bile acids and alcohol inhibit secretion of bicarbonate-rich
fluid by pancreatic ducts. Thus, the initial events in AP involve both ductal and acinar cells [13,14].
Irrespective of the causative factor, acinar injury is associated with early inflammatory reaction
within the pancreas, characterized by nuclear factor κB (NFκB) activation and cytokine production
in acinar cells, at least partially independent of trypsinogen activation [15–17]. As a consequence,
inflammatory cells, including neutrophils and monocytes, are activated and recruited to the pancreas,
exaggerating the damage of the gland as well as the inflammation [18]. In particular, neutrophils are the
source of tissue-degrading enzymes, reactive oxygen species, and further inflammatory cytokines [19].
Most recently, the formation of neutrophil extracellular traps has been documented within pancreatic
ducts, which enhances premature activation of trypsinogen [20,21]. Another consequence of local
inflammation is vascular injury within the pancreas, manifesting as endothelial activation and
endothelial injury, increased vascular permeability, activation of coagulation, and increased leukocyte
rolling, sticking and transmigration to pancreatic tissue [22,23]. In mild AP, the inflammatory response
is local and self-limiting, whereas in SAP, excessive systemic inflammation develops. The levels
of proinflammatory cytokines and acute phase proteins in systemic circulation correlate positively
with the severity of AP [17,18,24]. In SAP, trypsin, damage-associated molecular patterns, and
proinflammatory cytokines released from the inflamed pancreas lead to systemic vascular injury
with vascular leak syndrome and cardiovascular, kidney and lung failure [22,25]. Systemic endothelial
dysfunction may also manifest itself as diffuse activation of coagulation, with clinically significant
thrombotic complications observed in a part of patients with SAP [26,27].
Despite recent progress in understanding the early events in AP, more research is needed to enable
faster and more accurate prediction of a severe course of the disease as well as more specific and better
targeted treatment [3]. At present, prediction of SAP is based on clinical assessment at admission and
during the treatment [7]. The laboratory markers of trypsinogen activation or inflammation [24], the
severity scores based on computer tomography imaging, and the multi-parameter severity scores such
as bedside index of severity in AP (BISAP) or acute physiology and chronic health evaluation (APACHE)
have been proposed for prediction of SAP [28,29]. While they are helpful, they are far from perfect. The
biomarkers associated with systemic vascular injury may prove a useful alternative or supplementation.
The purpose of the review is to summarize current evidence regarding the interplay between
inflammation, coagulation and endothelial dysfunction in the early phase of AP. Practical aspects are
underscored, such as the possibilities to use the markers of endothelial dysfunction and activated
coagulation in early prediction of SAP, as well as the possibilities of targeting coagulation-inflammation
interactions in the treatment of SAP.
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2. Interrelations between Coagulation and Inflammation
Coagulation and inflammation clearly show reciprocal connections. Activation of coagulation
leads to stimulation of inflammatory mechanisms [30,31]. The contact of factor VII with tissue factor
(TF) is the main trigger for activation of coagulation. The complex formed by TF and activated
factor VII (VIIa) in the presence of factor X stimulates protease-activated receptors (PARs) [32,33].
Also thrombin as a serine protease activates PARs [34]. PARs are expressed by platelets and by
numerous immune cells such as monocytes, lymphocytes, macrophages, dendritic cells and mast cells,
as well as by endothelial cells [35]. Once thrombin affects PARs present on the membranes of platelets,
platelet activation occurs with shape change and the release of granules’ content, including adenosine
diphosphate, serotonin, thromboxane and chemokines [30]. Activation of platelets occurs as well in the
platelet phase of local hemostasis. Platelet stimulation leads to the release of soluble ligand for CD40
receptor (sCD40L) [36,37]. CD40 molecule belongs to the tumor necrosis factor (TNF) receptor family.
Soluble CD40L causes stimulation of TF production and the release of proinflammatory cytokines [38].
Acting on vascular endothelial cells, sCD40L, in addition to chemokine release, causes expression of
adhesion proteins, leading to rolling and sticking of leukocytes to the vascular endothelium, their
subsequent migration through the vascular wall and inflammatory infiltration of tissues [39]. Moreover,
thrombin may directly stimulate vascular endothelial cells, leading to increased vascular permeability,
expression of the adhesion proteins such as P-selectin, release of von Willebrand factor (vWF), as well
as increased production and release of cytokines [30].
The role of thrombin in the activation of inflammatory process is also related to its chemotactic
activity on monocytes, mitogenic activity on lymphocytes and stimulating effect on the production and
release of proinflammatory cytokines, particularly TNF-α, interleukin (IL)-1β and IL-6 [34]. In addition,
thrombin is capable of activating the complement system that plays an important role in humoral innate
immune response and modifies the specific immune response [40]. Thrombin can cause formation of
complement fragment C5a, an anaphylatoxin not related to the classic, alternative or lectin pathway of
complement activation [41].
Other serine proteases of the coagulation system, including a complex formed by TF and activated
factor VII, act directly on endothelial cells, macrophages and monocytes stimulating their proinflammatory
mechanisms, such as production of free radicals and expression of adhesion proteins [30,42]. Also, fibrin
formed as a result of activated coagulation as well as fibrin/fibrinogen-degradation products act in a
proinflammatory manner via activation of leukocytes [43,44] and influence the vascular endothelial cells,
which are stimulated to produce proinflammatory cytokines [45].
The relationships between coagulation and inflammation are two-way and are based on
positive feedbacks. Therefore, development of inflammation leads to activation of coagulation [30,31].
Trauma, tissue injury, hypoperfusion, hemodilution, hypothermia and acidosis induce acute
posttraumatic coagulopathy. Inflammation is an important causative factor [46]. The inflammatory
process activates the coagulation system, reduces the activity of natural anticoagulants and disturbs
functioning of the fibrinolysis system, leading to (microvascular) thrombosis [31]. Cytokines play an
important role in activation of the coagulation system and formation of fibrin, through their action in the
extrinsic coagulation pathway, i.e., induction of TF expression on endothelial cells and monocytes [47,48].
Recently, the contact system (or intrinsic pathway) has garnered increasing interest. Although
the deficiencies of factor XII (Hageman’s anomaly), plasma prekallikrein or high-molecular weight
kininogen do not lead to bleeding disorders, activation of the contact system has been implicated in
thrombosis [49]. Animal studies indicate that the inhibition of factor XII prevents thrombosis without
exerting increased bleeding risk [50]. Activation of the contact system also leads to the production of
inflammatory mediators, in particular bradykinin, a vasoactive substance with the potential to increase
vascular leakage. The contact system may be activated in vivo by inorganic polyphosphates released
from dense granules of activated platelets, or by neutrophil extracellular traps [51]. Interestingly, recent
studies suggest that activated endothelial cells may also form a surface that is capable of activating the
contact system [52].
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Increased activity of the coagulation system in the course of inflammation results not only from direct
activation of coagulation, but is also a consequence of the increase in plasma fibrinogen concentrations and
increased expression of endothelial TF and P-selectin [31]. Moreover, inflammation leads to increased levels
of C-reactive protein (CRP) and platelet activation with the exposure of procoagulant phospholipids [31,53].
Influence of CRP on coagulation is associated with facilitating interaction between monocytes and vascular
endothelial cells [54], as well as with increased production of TF by monocytes [55] and thus activation of
the extrinsic pathway [56]. Hypercoagulability observed in inflammation is also a result of inhibition of
natural anticoagulants and decreased fibrinolytic activity. CRP increases the expression of plasminogen
activator inhibitor-1 (PAI-1) by endothelial cells [57], while the production of prostacyclin is reduced [58].
This results in a reduction of the plasminogen activation and increased platelet aggregation.
Antithrombin inactivates thrombin as well as factors Xa, IXa, and VIIa linked with TF [31], resulting
in the inhibition of fibrin formation. In the case of free antithrombin, this effect is weak; however,
the thousand-fold increase of the inhibitory effect of antithrombin on thrombin and Xa occurs after
complexing with heparin or glycosaminoglycans present on the surface of endothelial cells [47]. In the
inflammatory state, accelerated degradation and inhibition of antithrombin activity occurs [31,59] as
well as reduced expression and accelerated degradation of endothelial cells’ glycosaminoglycans [60].
Moreover, the anticoagulant pathway of protein C is inhibited in inflammation [31]. Endotoxin,
IL-1β and TNF-α inhibit the expression of thrombomodulin and the endothelial cell protein C receptor,
thus reducing the formation of activated protein C and inhibiting its anticoagulant activity [61,62].
3. Endothelial Cells at the Interface of Coagulation and Inflammation
Endothelial cells have several important functions above being a barrier between blood and
tissues. They control vascular pressure and permeability, activation and adhesion of platelets
and leukocytes, coagulation and fibrinolysis. Their precise characteristics differ between organs
(with special characteristics of brain, lung and kidney vessels), and between venous and arterial
vascular beds. Endothelium is a dynamic tissue, quickly responding to various stimuli [63].
Endothelial cells are important for both hemostasis and inflammation. Healthy endothelium
under resting conditions exerts both anti-inflammatory and antithrombotic functions. Upon activation
by inflammatory factors, such as IL-1β and TNF-α, endothelial cells increase expression of adhesion
molecules, i.e., intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1
(VCAM-1), and E- and P-selectins, leading to increased adhesion of leukocytes and platelets and
transmigration of leukocytes through vascular wall. Inflammatory signals result in more procoagulant
phenotype of endothelial cells, with TF and factor V expression, production of PAI-1, downregulation of
thrombomodulin, and decrease of protein C synthesis [64]. Also, multiple stimuli, including thrombin,
histamine, leukotrienes, superoxides, complement components (C5a, C5b-9), vascular endothelial
growth factor (VEGF), vasopressin or epinephrine lead to degranulation of Weibel-Palade bodies and
the release of large multimers of vWF as well as other proteins (including P-selectin, IL-8, eotaxin-3,
angiopoietin-2, endothelin-1 and osteoprotegerin) [65].
Recently, the importance of angiogenic signaling pathways for vascular permeability became
evident. Two main signaling systems are known, namely VEGFs/VEGF receptors and angiopoietins/Tie
receptors. VEGF, also known as vascular permeability factor, is capable of strongly increasing vascular
permeability [66]. In systemic inflammation, high concentrations of VEGF are observed in blood [67].
Angiopoietin-2 is stored in Weibel-Palade bodies and rapidly released upon stimulation; its binding to
Tie-2 receptor leads to destabilization of the endothelium and increased vascular permeability [68].
4. Vascular Involvement in Acute Pancreatitis
In early pathogenesis of AP, microvascular abnormalities play an important role; in particular, SAP
is associated with early impairment of pancreatic blood flow (reviewed in [23]). In mild AP, pancreatic
capillary blood flow increases; however, SAP is associated with substantial early decrease in capillary
blood flow, with complete capillary stasis observed in almost 40% of pancreatic capillaries [69].
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Numerous clinical and experimental studies have shown that pancreatic ischemia plays an
important role in the development of AP and in the progression of the disease to severe necrotizing
pancreatitis [70–72]. As shown in a porcine model of severe AP, microcirculatory derangements are
responsible for the decreased pancreatic tissue oxygenation and tissue damage, and the severity of
microvascular disturbance is positively associated with mortality [73]. In AP evoked by pancreatic
ischemia followed by reperfusion, disturbance of pancreatic blood flow is a primary cause of this
disease. Numerous animal studies have indicated that pancreatic ischemia may be a causal factor in the
pathogenesis of AP [71,72,74,75]. A vascular mechanism plays an essential role in the development of
AP in some experimental settings [76]. Also, AP develops in clinical situations associated with
ischemia of the pancreas, such as shock, cardiac surgery, or pancreatic transplantation [23,70].
In human necrotizing AP of various etiologies, microcirculatory derangements were confirmed by
histopathological studies revealing microcirculatory intravascular thrombosis, intravascular stasis
and endothelial desquamation, as well as parenchymal swelling of the pancreas thus reflecting the
increased microvascular permeability preceding the development of pancreatic necrosis [77].
Moreover, improvement of pancreatic blood flow inhibits the development of AP and accelerates the
recovery [78–80]. In recent experimental animal studies, where AP was induced by cerulein and ischemia/
reperfusion, the course of acute pancreatitis was significantly milder after administration of digestive tract
hormones such as obestatin and ghrelin [81–83]. Administration of these hormones improved pancreatic
blood flow and, by their anti-inflammatory effect, led to acceleration of recovery from AP.
Microcirculatory changes in early SAP are not confined to the pancreas, but are also well
documented in other organs, i.e., colon and ileum, liver, lungs, kidneys, heart and brain [84–87].
In the early phase of organ failure due to SAP (only 3 h post induction of AP by taurocholate
in rats), edema, leukocyte adhesion to capillary walls and infiltration in tissues were observed in
histopathological examination of liver, kidney, lung, intestine, and spleen. Areas of necrosis were
detected in kidneys, intestine, spleen and lymph nodes. In pancreas, liver and kidneys, these changes
were also accompanied by microvascular thrombosis [87]. Experiments using intravital microscopy
confirmed increased capillary permeability and leukocyte rolling and sticking in distant organs in
the early phase of SAP, leading to decreased blood flow velocity [84,86]. Recently, the disturbances
and heterogeneity of capillary blood flow have been underscored as a cause of diminished blood
oxygenation in lungs and oxygen supply to tissues, despite preserved total organ perfusion [88].
Several vasoactive substances have been associated with microcirculatory impairment in AP,
including nitric oxide, bradykinin, endothelins, and platelet-activating factor (PAF) [89]. The role
of nitric oxide in AP is still controversial and has been extensively reviewed elsewhere [90].
Other mediators were with some success targeted in experimental AP. In severe porcine AP and in
various rat models of AP, pretreatment with the inhibitor of bradykinin B2 receptor (icatibant) showed
beneficial effects [91–94]. Endothelin-1, a potent vasoconstrictor, was shown to be up-regulated in
pancreatic endothelial cells by inflammatory stimuli, including cytokines, thrombin, and trypsin,
which was associated with impaired splanchnic microcirculation in SAP [95]. Inhibition of endothelin
receptor A attenuated reduced functional capillary density associated with experimental SAP in rats,
and ameliorated platelet-endothelial and leukocyte-endothelial cell interactions, reducing numbers
of stagnant platelets and leukocytes in pancreatic postcapillary venules [96]. PAF is a pleiotropic
phospholipid mediator, with roles in hemostasis (platelet activation), endothelial cell activation
(increase of capillary permeability), and inflammation (induction of cytokines, including IL-1β, TNF-α
and IL-6) [97]. Several PAF receptor antagonists were beneficial in experimental AP as reviewed
by Chen et al. [98]. Unfortunately, despite encouraging results of phase II human trials [99,100],
in randomized phase III trial, PAF antagonist lexipafant did not prevent new organ failure or
ameliorate systemic inflammatory response syndrome (SIRS) in patients with predicted SAP [101].
More recently, pretreatment with recombinant PAF acetylhydrolase was evaluated for the prevention
of post-endoscopic retrograde cholangiopancreatography (post-ERCP) pancreatitis in randomized
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multicenter trial. No beneficial effects on the incidence or severity of AP was shown, despite high
number of patients enrolled (600 patients) [102].
5. Laboratory Markers of Endothelial Activation and Injury in Acute Pancreatitis
Destabilization of the vascular endothelium, increased vascular permeability, disrupted vasomotor
regulation, and activated coagulation lead to early complications of acute pancreatitis [103,104].
Fluid sequestration in patients with AP within the first 48 h from admission is significantly associated
with SIRS criteria and the subsequent development of multiorgan failure [105].
VEGF is one of the most potent mediators capable of increasing vascular permeability. Several
groups have studied the involvement of VEGF in AP. The results of both animal and human studies
are, however, discrepant to some extent. Increased expression of VEGF was detected in the inflamed
pancreas and associated with the increased vascular permeability observed in the early phase of
AP [106,107]. The tyrosine kinase inhibitor of VEGF signaling attenuated almost completely the
increased vascular permeability in the pancreas during experimental AP [107]. In rats with mild AP
and severe necrotizing AP, serum VEGF concentrations were higher than in control animals [108].
However, infusion of VEGF in rats with SAP partially inhibited apoptosis in small intestine, kidney
and liver, without affecting water content of the lung, the volume of ascitic fluid or hematocrit,
suggesting a protective role of VEGF against endothelial injury in distant organs [108,109]. In the study
of Ueda et al. [109], serum VEGF in the early phase of AP was higher among patients with moderately
severe and severe AP, and was positively associated with kidney and liver failure, although not with
mortality. Conversely, Mentula et al. [110] did not observe differences in VEGF concentrations between
patients with AP who developed organ failure and those who did not.
A decoy VEGF receptor, soluble fms-like tyrosine kinase 1 (sFlt-1), has been strongly associated
with the severity of sepsis [111]. We observed positive correlations between soluble sFlt-1 and the
severity as well as complications of AP, such as acute kidney injury and activated coagulation [112].
Angiopoietin-2 has been proposed as a causative factor and a laboratory marker of endothelial
cells’ destabilization and increased vascular permeability. In patients with AP, higher angiopoietin-2
predicted SAP, multiorgan failure, infectious complications and bowel ischemia as well as
mortality [113,114]. Increased angiopoietin-2 was positively associated with the severity of AP,
particularly kidney injury in the early phase of AP [104]. In recent years, angiopoietin-2 emerged as
one of the most promising biomarkers for the early prediction of AP severity (Table 1).
Angiopoietin-2 is known to be stored in Weibel-Palade bodies of endothelial cells. The main
protein of Weibel-Palade bodies, namely vWF, is also increased in plasma during SAP. In rats, SAP
was associated with increased plasma vWF and soluble endothelial protein C receptor, as well as with
increased endothelial cell apoptosis in the aorta as compared to the mild AP [115]. Increased plasma
vWF was also reported in humans with SAP: its concentrations correlated positively with the severity
of organ failure, APACHE III and sequential organ failure assessment (SOFA) scores, and significantly
predicted acute lung injury [116] (Table 1). Several reports were published showing coincidence
between AP and thrombotic thrombocytopenic purpura [117–119]. Morioka et al. [117] found highly
increased concentrations of vWF (mean on admission 402%) coinciding with low activities of a
disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS-13) among
13 SAP patients without disseminated intravascular coagulation (DIC). Mean ADAMTS-13 activity
on admission was 37%, decreased to 32% on day 2 and subsequently increased. ADAMTS-13 activity
negatively correlated with the APACHE II score as well as with markers of inflammation (IL-6, IL-8,
fibrinogen, CRP, leukocytes) and pancreatic enzymes (serum amylase, elastase 1, trypsin and lipase).
No ADAMTS-13 inhibitor was detected. Consequently, ultra large vWF multimers were detected in
patients with the highest vWF/ADAMTS-13 ratios.
Also, serum concentrations of osteoprotegerin, another protein stored and released from
Weibel-Palade bodies upon endothelial activation, are significantly higher in patients with SAP as
compared to mild AP [120].
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Table 1. Diagnostic accuracy of laboratory markers of endothelial activation or injury measured in serum or plasma for the prediction of severity, complications and
mortality of acute pancreatitis (AP).
Laboratory Test Studied Group Time of Blood Collection Outcome Variable (Number of Cases) Values Associated withOutcome Variable Se., %
1 Sp., % 2 AUC 3 Ref. 4
Angiopoietin-2
28 patients with AP from
University of Pittsburgh
Medical Center
Within 3 days from the onset
of pain 5
Severe AP (persistent organ failure >48 h or
death) (6 patients form Pittsburg and 14
from Greifswald)
>1.91 ng/mL 83 91 0.940
[113]
123 patients with AP from
Greifswald University >2.94 ng/mL 93 63 0.790
25 patients with AP At 12 h from admission (admissionwithin 72 h from the onset of pain)
Severe AP according to 1992 Atlanta
classification (7 patients) >10 ng/mL 100 88 0.970 [121]
115 patients with AP (subsample
from PROPATRIA trial cohort)
Within 5 days from admission
(median 3 days from the
onset of pain)
Severe AP (organ failure or pancreatic
necrosis) (37 patients) >4.56 ng/mL 81.1 73.2 0.851
[114]
Multiorgan failure (18 patients) >5.01 ng/mL 72.2 73.2 0.784
Infectious complications of AP (39 patients) >4.51 ng/mL 79.5 76.3 0.816
Soluble fms-like
tyrosine kinase 1
66 consecutive adult patients
with AP
At 24 h from the onset of pain Severe and moderately severe AP according
to 2012 Atlanta classification (20 patients)
>139 pg/mL 94% 63% 0.808
[112]
At 48 h from the onset of pain >120 pg/mL 78 77 0.791
Soluble E-selectin
56 patients with AP At admission (≤48 h from theonset of pain)
Severe AP according to Ranson’s score and
Balthazar CT grading (28 patients) increased NR
6 NR 6 0.802 [122]
15 consecutive patients with AP
At admission (≤6 h from the onset
of pain) and on two subsequent
days (pooled results)
Severe AP according to 1992 Atlanta
classification (5 patients) >3.92 ng/mL 60 90 0.780 [123]
69 adult patients with severe AP At admission (≤48 h from theonset of pain)
Acute respiratory distress syndrome in the
course of severe AP (39 patients) >165.6 ng/mL 48.3 86.7 0.704 [116]
Soluble ICAM-1
15 consecutive patients with AP
At admission (≤6 h from the onset
of pain) and on two subsequent
days (pooled results)
Severe AP according to 1992 Atlanta
classification (5 patients) >80.4 ng/mL 73.3 70 0.684 [123]
69 adult patients with severe AP At admission (≤48 h from theonset of pain)
Acute respiratory distress syndrome in the
course of severe AP (39 patients) >711.2 ng/mL 61.5 93.3 0.787 [116]
Soluble
thrombomodulin
73 patients with AP On day 3 from the onset of pain Death (12 patients) <75 ng/mL 100 77 NR 6 [124]
104 patients with AP At 48 h from the onset of pain Pancreatic necrosis (32 patients) >71.5 µg/L 75 99 0.949 [125]
27 patients with AP At admission Death (5 patients) >32 TU/mL 80 91 0.876 [126]
von Willebrand
factor (antigen) 69 adult patients with severe AP
At admission (≤48 h from the
onset of pain)
Acute respiratory distress syndrome in the
course of severe AP (39 patients) >169.2% 43.2 93.3 0.686 [116]
1 diagnostic sensitivity; 2 diagnostic specificity; 3 area under receiver operating characteristic curve; 4 reference number; 5 the onset of pain due to AP is considered the onset of the disease;
6 not reported.
Int. J. Mol. Sci. 2017, 18, 354 8 of 25
Adhesion proteins, including E- and P-selectins, ICAM-1 and VCAM-1 have been studied as
markers of endothelial activation or injury in AP. E-selectin is synthesized de novo by endothelial
cells stimulated by IL-1, TNF-α, endotoxin and oxidative stress. Its soluble form occurs due to
shedding from the surface of activated endothelial cells. P-selectin is stored in Weibel-Palade
bodies, and thus may be rapidly released upon stimulation of endothelial cells, e.g., by thrombin
or histamine. Additionally, upon stimulation by TNF-α and IL-1β, endothelial cells synthesize
P-selectin. In experimental AP, prophylactic inhibition of P-selectin resulted in reduced platelet
activation, platelet-endothelium and leukocyte-endothelium interactions and reduced pancreatic tissue
inflammation and necrosis [127]. Both P- and E-selectins are overexpressed in lung tissue during
experimental AP. Their up-regulation was associated with increased sequestration of neutrophils and
pulmonary injury observed in histological examination [128]. ICAM-1 is constitutively expressed
by endothelial cells, but the expression highly increases upon inflammatory stimulation. VCAM-1
expression is specific to endothelium; together with ICAM-1, it is involved in leukocyte adhesion and
rolling. Increased ICAM-1 expression was reported in lungs of rats with SAP [129]. Blocking ICAM-1
with an antibody resulted in reduced neutrophil sequestration, decreased microvascular permeability
and improved lung histology [129]. Frossard et al. [130] also found increased ICAM-1 in serum,
pancreas and lungs of mice with AP induced with cerulein or with choline-deficient, ethionine-rich
diet. Both pancreatitis and lung injury were diminished but not completely prevented in mice with
ICAM-1 deficiency. In porcine model of SAP, increased expression of adhesion proteins was shown:
platelet-endothelial cell adhesion molecule-1 in liver, kidney and pancreas, VCAM-1 in kidney, and
P-selectin in liver [131].
Increased soluble E-selectin has been proposed as a marker of severe AP in several studies
(Table 1). Wereszczynska-Siemiatkowska et al. [122] reported increased soluble E-selectin during
first 10 days from admission among patients with SAP, as compared to those with mild AP and to
patients with non-AP acute abdominal pain (mainly acute biliary tract diseases). At admission of
AP patients, strong correlations were observed between soluble E-selectin and IL-6 concentrations,
polymorphonuclear elastase activity, as well as oxidative stress markers (serum malondialdehyde
and 4-hydroxyalkenals) [122]. Of note, patients with severe AP had also increased IL-10 serum
concentrations, especially during the first two days from admission, and positive correlation was
found between E-selectin and IL-10 [122]. In another study, soluble E-selectin, ICAM-1, TF and vWF
were shown to be significantly higher in SAP associated with acute respiratory distress syndrome; all
studied endothelial markers correlated positively with APACHE III and SOFA scores, and negatively
with oxygenation index (PaO2/FiO2) during the first 10 days of hospital stay due to AP [116].
Also, Powell et al. [132] and Ida et al. [126] reported higher soluble E-selectin in patients with SAP,
especially in those who subsequently died, as compared to mild AP. Moreover, during 3 days from
admission, E-selectin concentrations were increasing in severe disease in contrast to mild AP [132].
Nakae et al. [133] observed positive correlation between soluble E-selectin and TNF-α in the early
phase of human AP; both mediators were positively associated with AP severity. Hynninen et al. [134]
reported similarly increased soluble E-selectin in patients with SAP and with severe sepsis, positively
correlated with SOFA scores. However, there are also contradictory reports. It was suggested that the
peak soluble E-selectin concentrations are observed late (after 72 h from the onset of AP symptoms)
and can therefore not be used as an early marker of AP severity [135,136]. During first 6 h from the
onset of pain, Pezzilli et al. [123] did not observe higher soluble E-selectin in AP patients compared to
healthy controls; however, it was higher in SAP than in mild AP. Ida et al. [126] did not show significant
difference in soluble E-selectin on admission and on subsequent days in those who died from AP
compared to survivors. Nonetheless, both mild and severe AP were associated with concentrations
above the reference limit.
Reports regarding soluble P-selectin in patients with AP are scarce. In a small study of
Powell et al. [132], serum soluble P-selectin concentrations during 3 days from admission did not
differ between mild and severe AP, but were significantly higher in non-survivors than survivors.
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To the contrary, Pezzilli et al. [123] reported lower soluble P-selectin in SAP patients’ sera as compared
to those with mild AP and healthy controls.
Soluble ICAM-1 has been associated with the severity of human AP (Table 1). Pezzilli et al. [123]
observed higher concentrations of soluble ICAM-1 in patients with SAP versus mild AP. This result is,
however, depreciated by the fact that the levels in patients with AP were not significantly different
compared to healthy volunteers. Siemiatkowski et al. [116] have shown that soluble ICAM-1 may serve
as a marker of AP-associated lung injury. In this study, strong positive correlations were observed
between plasma-soluble ICAM-1 and severity of organ dysfunction (APACHE III and SOFA scores) in
SAP patients. Nakae et al. [133] observed higher soluble ICAM-1 in patients who died from AP than
in survivors.
Studies of soluble VCAM-1 in patients with AP are inconclusive. Serum VCAM-1 in AP patients
on admission was lower than in controls and did not correlate with AP severity in one study [123],
while it was higher among non-survivors of SAP and positively correlated with ICAM-1 and TNF-α in
another study [133].
Elevated plasma concentrations of thrombomodulin in inflammation are caused by shedding of
membrane-bound thrombomodulin from endothelial cells by neutrophil elastase. In a small study,
Ida et al. [126] have shown that increased plasma concentrations of soluble thrombomodulin was
positively associated with the severity of AP and was higher in patients who died. Mantke et al. [124]
studied soluble thrombomodulin during the first 28 days after the onset of symptoms of AP: starting
from day 3, non-survivors had significantly higher concentrations than survivors. The clinical studies
consistently reported positive association between plasma thrombomodulin in the early phase of AP
and more severe disease [124–126] (Table 1). Plasma tissue factor pathway inhibitor (TFPI) in human
AP was shown to be higher in patients with SAP as compared to mild AP, and was positively correlated
with inflammatory mediators, thrombomodulin and PAI-1, consistent with the assumption that plasma
TFPI levels reflect endothelial injury rather than anticoagulation [137].
Recently, levels of endothelial-specific microRNAs (miR-551-5p and miR-126a-5p) were associated
with the severity of human AP [138].
6. Disturbances of Hemostasis in Relation to Inflammation in Acute Pancreatitis
In experimental and human AP, abnormalities were reported regarding all aspects of
hemostasis [26]. Decreased numbers of platelets and increased platelet activation were observed
in the early phase of AP [139–143]. Plasma TF concentrations were increased [116,144,145].
The levels of prothrombin, fibrinogen and factor X gradually decreased [146], and prolonged
clotting times (prothrombin time, activated partial thromboplastin time and thrombin time) were
observed [139,146,147]. Decreased concentrations of natural anticoagulants, especially protein C and
antithrombin, were consistently reported [139,148–150]. Activity of tissue plasminogen activator (tPA)
and PAI-1 was increased [151,152]. A complex of α2-plasmin inhibitor with plasmin was increased
in patients with the most severe AP [142]. These changes are consistent with the activation of the
coagulation system, following local and systemic inflammation, leading to consumptive coagulopathy.
The degree of coagulation abnormalities in AP depends on the severity of inflammation [146,147].
In mild pancreatitis, thrombosis may be limited to pancreatic microcirculation. In severe systemic
inflammation, DIC may occur [139,153]. Activation of fibrinolysis secondary to activated coagulation
results in increased concentrations of fibrin/fibrinogen degradation products, including D-dimer, that
are significantly correlated with inflammatory markers and AP severity [142,143,147,150,154].
The classic Virchow’s triad of factors predisposing to thrombosis, i.e., procoagulant changes in the
blood components, procoagulant properties of the vessel wall and decreased blood flow velocity, can
be observed in SAP. Consequently, various clinically relevant thrombotic complications are observed
in human AP, ranging from localized thrombosis [155–158] and pulmonary thromboembolism [159] to
DIC [153,160]. Both thrombotic and hemorrhagic complications were associated with deaths due to
AP [27].
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Even in the absence of clinically significant thrombotic complications, laboratory tests reveal the
activation of coagulation and fibrinolysis, related to the severity of AP. Maeda et al. [142] reported
significant correlations between laboratory parameters of DIC and the severity of AP measured in the
five-stage Japanese scoring system: more severe AP was associated with lower platelet counts and
antithrombin concentrations as well as higher levels of D-dimer, fibrin/fibrinogen degradation product
E, and thrombin-antithrombin complexes. All the parameters were also significantly associated with
mortality (Table 2); and the diagnosis of DIC was much more prevalent among patients who died
(79% versus 10% of patients) [142]. Also, longer PT, APTT, higher fibrinogen and D-dimer, lower
protein C and antithrombin, lower plasminogen, and higher PAI-1 on admission and 24 h thereafter
were associated with organ failure (pulmonary, kidney or cardiovascular) in the course of AP in
humans [161] (Table 2). Of note, high D-dimer concentrations in SAP were observed already at
admission (1–2 days from the onset of symptoms), but persisted during the subsequent week and even
during remission of AP [143,147,150]. Also, patients with moderately severe AP were characterized by
higher D-dimer and lower protein C levels as compared with mild AP [162]. Plasma TF concentrations
were significantly increased in SAP during the first 10 days from admission, and significantly correlated
with APACHE III and SOFA scores as well as with PaO2/FiO2 [116]. The admission TF concentrations
significantly predicted AP-associated lung injury [116] (Table 2). In patients who eventually died from
AP as compared to patients who survived, natural anticoagulants (antithrombin and protein C, but not
protein S) were lower, and increased levels of PAI-1 and D-dimer were observed during the preceding
period [150,161,163]. In patients with SAP as defined by the original 1992 Atlanta classification
(organ failure and/or local complications), the development of organ failure was associated with
decreased protein C concentrations as well as decreased activated protein C [148]. Protein C and
activated protein C levels correlated with the numbers of activated monocytes [148].
The results of the studies that reported diagnostic accuracy of laboratory markers of hemostasis
are summarized in Table 2. Most reliable diagnostic accuracy was consistently reported for D-dimer
measured at admission for the prediction of (multi)organ failure [161,164] and antithrombin for the
prediction of death [142] (Table 2).
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Table 2. Diagnostic accuracy of laboratory markers of hemostasis measured in whole blood (platelet count) or plasma (other markers) for the prediction of severity,
complications and mortality of acute pancreatitis (AP).




Se., % 1 Sp., % 2 AUC 3 Ref. 4
Platelet count 139 consecutive patients with AP At admission Death (14 patients) <92 × 103/µL 75 71 0.850 [142]
D-dimer
139 consecutive patients with AP At admission Death (14 patients) >6.1 µg/mL 85 67 0.783 [142]
91 consecutive patients with AP At admission Organ failure: pulmonary or kidney failure, or
shock (24 patients)
>0.414 µg/mL 90 89 0.908
[161]
24 h from admission >0.551 µg/mL 90 81 0.916
38 consecutive patients with AP At admission
Organ failure (23 patients) >0.4 µg/mL 81.7 54.2 0.683
[150]
Death (14 patients) >0.4 µg/mL 90.9 58.3 0.708
45 consecutive adult patients with
severe AP
Day 0–2 from admission (mean value) Multiorgan dysfunction syndrome (16 patients) >0.812 µg/mL 81 90 0.899
[154]Pancreatic infection (14 patients) >0.762 µg/mL 100 87 0.968
Day 0–2 from admission (maximum value) Multiorgan dysfunction syndrome (16 patients) >0.975 µg/mL 81 79 0.885
Pancreatic infection (14 patients) >0.975 µg/mL 93 81 0.935
36 pediatric patients with AP
(aged 1–17 years) At admission Multiorgan failure (4 patients) >1.189 µg/mL 100 87.5 0.914 [164]
173 adult patients with AP At admission (≤96 h from the onset of pain 5) Critical AP (persistent organ failure plusinfected necrosis) (47 patients) >0.67 µg/mL 83 68 0.810 [165]
106 patients with mild to
moderately severe AP
Within 24 h from admission (≤48 h from the
onset of pain)
Moderately severe AP according to 2012
Atlanta classification >0.91 µg/mL 62.2 84.1 0.747 [162]
Fibrin/fibrinogen
degradation product-E 139 consecutive patients with AP At admission Death (14 patients) >894 ng/mL 93 73 0.873 [142]
Antithrombin
139 consecutive patients with AP At admission Death (14 patients) <69% 81 86 0.926 [142]
91 consecutive patients with AP 24 h from admission Organ failure: pulmonary or kidney failure, orshock (24 patients) <75.5% 62 89 0.770 [161]
38 consecutive patients with AP At admission
Organ failure (23 patients) ≤71% 66.7 78.6 0.748
[150]
Death (14 patients) ≤71% 70.8 81.8 0.830
Protein C 38 consecutive patients with AP At admission
Organ failure (23 patients) ≤60% 62.5 64.3 0.683
[150]
Death (14 patients) ≤60% 70.8 63.6 0.691
Thrombin-antithrombin
complex 139 consecutive patients with AP At admission Death (14 patients) >11 ng/mL 79 72 0.768 [142]
Tissue factor
19 patients with alcoholic SAP At admission (≤48 h from the onset of pain) Pancreatic necrosis (11 patients) >350 pg/mL 60 100 0.773 [144]
48 consecutive patients with AP At inclusion into study (median duration of
pain 34 and 25 h in mild and severe AP)
Severe AP according to 1992 Atlanta
classification (21 patients)
>32 pg/mL 86 48
0.679 [145]
>46 pg/mL 62 74
69 adult patients with severe AP At admission (≤48 h from the onset of pain) Acute respiratory distress syndrome in thecourse of severe AP (39 patients) >168.4 pg/mL 61.1 90.0 0.757 [116]
1 diagnostic sensitivity; 2 diagnostic specificity; 3 area under receiver operating characteristic curve; 4 reference number; 5 the onset of pain due to AP is considered the onset of the disease.
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On the other hand, activated platelets and coagulation have been shown to drive inflammation
in AP. Platelets enhance leukocyte rolling, sticking and transmigration in pancreatic venules in
the early phase of AP [96,166]. Platelet P-selectin appears crucial for leukocyte recruitment and
rolling in inflamed venules of the pancreas [167,168]. PAR-2 signaling was implicated in AP
pathogenesis; its inhibition protected mice against experimental biliary pancreatitis and AP-associated
lung injury [169,170].
These observations have led to the assumption that anticoagulant or antithrombotic treatment in
AP may result not only in reduction of (micro) thrombosis and improved microcirculation but also in
reduced local and systemic inflammation.
7. Therapeutic Effects of Anticoagulants in Acute Pancreatitis
7.1. Heparin
Heparin as a cofactor of antithrombin inhibits thrombin activity as well as factor Xa activity and
thus thrombin formation. Heparin attenuates not only procoagulant but also proinflammatory effects
of thrombin. Moreover, heparin in a complex with antithrombin or heparin cofactor II is able to reduce
activity of trypsin and chymotrypsin as well as the conversion of trypsinogen into trypsin [171,172].
Various experimental studies have shown the anti-inflammatory effect of heparin, administered both
in a protective and therapeutic manner in AP [171,173–178]. Earlier studies have been summarized by
Hackert et al. in 2004 [179].
In humans, several trials explored the utility of unfractioned or low molecular weight heparin
(LMWH) to prevent post-ERCP pancreatitis in high-risk patients [180–183]. Neither of the studies
demonstrated reduced AP or SAP ratios in the treatment groups. A meta-analysis [177] performed in
2011 that included the four trials cited above (1438 patients in total) did not show significant benefit
of prophylactic heparin in prevention of post-ERCP pancreatitis (relative risk 0.67, 95% confidence
interval 0.44–1.03, p = 0.07) or post-ERCP SAP (relative risk 0.62, 95% confidence interval 0.15–2.60,
p = 0.51). There were no differences between unfractioned and low molecular weight heparin. Of note,
no increased bleeding risk was shown as well (relative risk for ERCP-related hemorrhage 0.84, 95%
confidence interval 0.34–2.03, p = 0.69).
Heparin has been used in the treatment of SAP caused by severe hypertriglyceridemia. Such
treatment is justified by the ability of heparin to stimulate lipoprotein lipase activity [184]. Several case
reports or case series suggested effectiveness of heparin, usually administered in conjunction with
insulin, in lowering triglyceride concentrations in such patients [184–187]. The results of a clinical trial
evaluating the effects of LMWH and intensive insulin therapy in SAP were published in 2014 [188].
The trial included 134 adult patients with SAP treated in single-center (General Hospital of PLA,
Beijing, China), randomly assigned to four groups: control group treated conventionally, intensive
insulin therapy group, LMWH group (5000 U every 12 h) and combined treatment group (insulin plus
LMWH), in addition to conventional therapy. Authors reported reduced lengths of stay, incidence of
multiorgan failure, need for surgery and mortality in treatment groups, with best results of combined
treatment. Four patients (12%) died in the control group (conventional treatment), as compared to one
death (3%) in the intensive insulin therapy group, one death (3%) in the LMWH group and no deaths
in the group administered combined therapy.
The use of LMWH for treatment of SAP was also evaluated in a multicenter randomized trial
that recruited 265 patients from four hospitals from China [189,190]. LMWH was administered in
dose 100 µg/kg/day starting at admission, until day 7 of the hospital stay. Balthazar computed that
the tomography scores at the end of the first and second week of the hospital stay were better in the
treatment group than in the control group (conservative treatment), as well as APACHE II score for
week 2. The incidence of acute respiratory distress syndrome, pancreatic encephalopathy, multiorgan
failure, and mortality (10.4% versus 30.6%) was lower in the treatment group.
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7.2. Activated Protein C
In experimental SAP, treatment with activated protein C (APC) resulted in decreased inflammation
(decreased expression of pancreatic TNF-α and IL-1β proteins, decreased serum TNF-α, IL-8 and IL-6),
increase in pancreatic expression of endothelial protein C receptor and thrombomodulin, and reduced
severity of pancreatic morphological changes, including necrosis [149,191,192]. Bacterial translocation
to mesenteric lymph nodes and to pancreas was reduced in APC-treated rats with SAP [192]. However,
a contradictory report was also published, illustrating that administration of APC did not result in
improved histopathologic scores of the pancreas and, in fact, was associated with significantly higher
serum IL-6 [193]. In the study of Alsfasser et al. [194], despite no difference in the histopathologic
scores of the pancreas, rats with SAP that were treated with APC presented reduced pancreatic and
pulmonary inflammation (reduced myeloperoxidase activity) and improved survival.
A small clinical trial was undertaken to evaluate safety and efficacy of the treatment with APC in
AP (APCAP study) [195]. A prospective double-blind randomized study included 32 patients with SAP
and no sepsis from a single center (Helsinki University Central Hospital, Helsinki, Finland). Patients
were admitted within 96 h from the onset of pain. APC was administered intravenously for 96 h in a
fixed dose of 24 µg/kg/h; physiologic saline was used as placebo. All patients received the treatment
according to the initial randomization. No significant difference was observed between treatment and
placebo groups regarding the primary efficacy endpoint, i.e., the change in SOFA score between the
start of the study drug (day 0) and day 5. In fact, a small non-significant difference in advantage of
placebo was found. Three deaths due to multiple organ failure occurred in the treatment group and
none in the placebo group (autopsy excluded bleeding as a cause of the deaths). The only significant
difference was the increase in total and conjugated bilirubin in the treatment group. No serious
bleeding occurred in treated patients; four patients had minor bleeding (from mouth, nose, or urinary
tract) versus two patients in the placebo group. Recent analysis revealed that APC did not alleviate
coagulative disorders in patients included in the APCAP study; rather, the treatment with APC was
associated with retarded recovery from coagulopathy [196].
7.3. Soluble Thrombomodulin
Eguchi et al. [197] performed a retrospective analysis of 54 adult patients with SAP diagnosed
according to Japanese severity scoring system, treated in a single center (Osaka Saiseikai Nakatsu
Hospital, Osaka, Japan), of whom 24 developed DIC and were therefore treated with recombinant
human soluble thrombomodulin (rTM). The study included patients in whom treatment started within
the first 48 h from the onset of pain. Patients who were subsequently treated with rTM had on average
more severe disease, with higher APACHE II and SOFA scores on admission, i.e., before treatment.
Acute necrotizing collections within the pancreas were equally prevalent in both treated and untreated
groups at admission. rTM was administered in dose 380 or 130 U/ kg/day for patients on hemodialysis.
The treatment was introduced in those who were diagnosed with DIC and continued until remission
of DIC. Other aspects of AP treatment did not differ between the groups. The length of hospital stay,
need for intensive care, length of intensive care unit stay, incidence of persistent organ failure, or
mortality did not differ between the groups. Walled-off necrosis at 4 weeks from admission or later
was significantly less prevalent in the treated group (29% versus 57% of patients). No serious adverse
events (e.g., bleeding) were recorded in the treatment group.
7.4. Other Anticoagulants
In a recent experimental study, pretreatment with low doses of acenocoumarol, a vitamin K
antagonist, attenuated ischemia/reperfusion-induced AP and was associated with reduced leukocyte
inflammatory infiltration of the pancreas as well as diminished pancreatitis-induced increase in
serum IL-1β concentrations [198]. The results were confirmed in another model of experimental AP,
i.e., cerulein-induced AP in rats [199]. Since acenocoumarol is a commonly used antithrombotic drug
Int. J. Mol. Sci. 2017, 18, 354 14 of 25
with well-known safety profile, its usefulness in prevention of AP among patients with pancreatic
circulation disorders would be worth studying.
Pretreatment with antithrombin was shown to ameliorate cerulein-induced AP in rats [200].
Edema, inflammation and necrosis of the pancreas were partially reduced and serum concentrations
of IL-6, TNF-α, and high-mobility box group 1 protein were diminished in mice pretreated with
antithrombin. Similar results were obtained with pretreatment with low molecular weight heparinoid,
danaparoid sodium, that was also shown to inhibit cerulein-induced NFκB activation [201].
Andersson et al. [202] evaluated the effects of pretreatment with active side-inactivated factor
VIIa in rats. AP was then induced by infusion of sodium taurodeoxycholate into common bile duct.
Myeloperoxidase activity was significantly reduced in ileum and lungs of pretreated animals, and
serum concentrations of inflammatory markers were lowered.
8. Conclusions
The interplay between inflammation, coagulation and endothelial activation is involved in the
earliest local events in acute pancreatitis (AP), and is associated with the early phase of systemic
disease in severe AP (SAP), although many aspects remain unknown. From the current evidence on
this subject, there are several practical conclusions: (1) Systemic inflammation as seen in SAP is not
rarely associated with thrombotic disorders, and the activation of coagulation may further aggravate
inflammation. Laboratory tests in SAP often reveal abnormalities of coagulation, while clinically
relevant disorders of coagulation in AP are associated with significantly worse prognosis; (2) Markers
of coagulation/fibrinolysis measured early in the course of AP, in particular D-dimer, are significantly
associated with AP severity, and may therefore be used to assist treatment decisions and prognosis;
(3) Markers of endothelial dysfunction, in particular angiopoietin-2, may prove even more useful;
however, we need robust, routine and standardized laboratory tests, currently available only for sFlt-1;
(4) There are severe difficulties in translation between animal experiments using anticoagulant or
antithrombotic medications and their use in humans. There may be several reasons. Patients with AP
form a much more heterogeneous group than the experimental animals, both regarding the causes of
AP and the time from the disease onset to the start of treatment. In substantial proportion of patients,
systemic inflammation and organ failure are present already at admission. Also, there are difficulties
in recruiting enough patients for clinical trials; (5) Nevertheless, some reports from clinical trials with
low molecular weight heparin treatment are promising. However, the results have to be corroborated
by other groups before this treatment can be recommended; (6) Although the use of anticoagulants
was rarely associated with significant benefits in clinical trials, there were also no significant bleeding
complications. This fact encourages the use of such drugs in the treatment of thrombotic complications
of AP.
Further clarification of the relationships between inflammation, pancreatic blood flow,
coagulation system, endothelial involvement and the development and course of AP is needed.
Several anticoagulant or antithrombotic drugs have ameliorated AP severity in experimental designs,
and their therapeutic potential is still worth being tested in patients.
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Abbreviations
AP acute pancreatitis
NFκB nuclear factor κB
SAP severe acute pancreatitis
TF tissue factor
PAR protease-activated receptor
sCD40L soluble CD40 ligand
TNF tumor necrosis factor
vWF von Willebrand factor
IL interleukin
CRP C-reactive protein
PAI-1 plasminogen activator inhibitor-1
ICAM-1 intercellular adhesion molecule-1
VCAM-1 vascular cell adhesion molecule-1
VEGF vascular endothelial growth factor
PAF platelet activating factor
ERCP endoscopic retrograde cholangiopancreatography
SIRS systemic inflammatory response syndrome
sFlt-1 soluble fms-like tyrosine kinase 1
APACHE acute physiology and chronic health evaluation
SOFA sequential organ failure assessment
ADAMTS-13 disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13
DIC disseminated intravascular coagulation
CT computed tomography
TFPI tissue factor pathway inhibitor
tPA tissue plasminogen activator
LMWH low molecular weight heparin
APC activated protein C
rTM recombinant human soluble thrombomodulin
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